Larimar Therapeutics, Inc. (LRMR): Total Liabilities
$67.76M
As of 2025-12-31
$37.92M
As of 2026-06-30
+63.5%
3-year compound annual growth
+35.2%
5-year compound annual growth
+13.0%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $67.76M | +138.5% | 2026-03-19, Balance as of period end |
| 2024-12-31 | $28.41M | +99.9% | 2026-03-19, Balance as of period end |
| 2023-12-31 | $14.21M | -8.3% | 2025-03-24, Balance as of period end |
| 2022-12-31 | $15.50M | +8.8% | 2024-03-14, Balance as of period end |
| 2021-12-31 | $14.25M | -4.9% | 2023-03-14, Balance as of period end |
| 2020-12-31 | $14.99M | +154.4% | 2022-03-25, Balance as of period end |
| 2019-12-31 | $5.89M | -79.3% | 2021-03-04, Balance as of period end |
| 2018-12-31 | $28.49M | +4.4% | 2020-03-05, Balance as of period end |
| 2017-12-31 | $27.29M | +175.9% | 2019-03-14, Balance as of period end |
| 2016-12-31 | $9.89M | -50.5% | 2018-03-09, Balance as of period end |
| 2015-12-31 | $20.00M | +52.9% | 2017-03-10, Balance as of period end |
| 2014-12-31 | $13.08M | +348.6% | 2016-03-15, Balance as of period end |
| 2013-12-31 | $2.92M | n/a | 2015-03-25, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Larimar Therapeutics, Inc. (LRMR) | 2025-12-31 | $67.76M | +138.5% |
| XBiotech Inc. (XBIT) | 2025-12-31 | $9.73M | -42.2% |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | $72.68M | +65.0% |
| Whitehawk Therapeutics, Inc. (WHWK) | 2025-12-31 | $14.52M | -18.6% |
| Ovid Therapeutics Inc. (OVID) | 2025-12-31 | $20.27M | -15.3% |
| Monopar Therapeutics (MNPR) | 2025-12-31 | $2.89M | -45.0% |
| CytomX Therapeutics, Inc. (CTMX) | 2025-12-31 | $52.56M | -56.6% |
| Veradermics, Inc (MANE) | 2025-12-31 | $9.16M | +94.1% |
| Elite Pharmaceuticals Inc (ELTP) | 2026-03-31 | $39.41M | -8.1% |
Compare LRMR, XBIT, PRLD, WHWK side by side · Screen every company in Pharmaceutical Preparations ↗